HBOT Conversations:
Dr. Peter Canaday (Part 1)
Dr. Peter Canaday has published work in Applied Physiology, Respiratory Medicine, and Diagnostic Radiology. He has presented at National (USA) and International meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on National, State, and Local advisory committees, and given testimony at the State Legislative level in the USA.
Dr. Canaday’s experience with Hyperbaric Oxygen Therapy dates back to the 1980s when he studied HBOT under Dr. Eric Kindwall, “The Father of Hyperbaric Medicine”. Dr. Canaday also co-founded the Hyperbaric Medicine Department at St. Anthony Hospital in Lakewood, Colorado.
From 2007, Dr. Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at a Midlands region DHB and served as Head of Department before retiring in March 2021.
Watch the Podcast
HBOT News welcomes Dr. Peter Canaday. Dr. Canaday now lives primarily in New Zealand, but his history with medicine and Hyperbaric Oxygen Therapy dates back over 40 years to the United States.
In this HBOT News Network Conversations, Dr. Canaday spends the first several minutes providing listeners with his biography and medical background. He also dives into his experience with Hyperbaric Oxygen Therapy in the 1980s.
The subject of PTSD and recent Hyperbaric research arises, and Dr. Canaday expands on the topic by referencing two research articles from Dr. Paul G. Harch –
Dr. Canaday further explains, “There is a recruitment of the anti-inflammatory enzymes and a suppression of the pro-inflammatory enzymes that can be achieved through even these lower pressure units. And so we’re beginning to see now the potential mechanism for which Hyperbaric Therapy, whether with or without oxygen, may be effective.”
The remainder of this HBOT News Conversation is specific to the topic of COVID-19. di Girolamo starts the conversation discussing the struggles for long-hauler COVID patients and the growing number of vaccine injuries as a result of the COVID-19 vaccine. Dr. Canaday agrees that the scientific inquiry for COVID-19 and the available information for associated vaccines has been widely suppressed. He continues that even the data which represent conclusions from peer-reviewed literature has been simply ignored, or set aside without discussion.
In response, Dr. Canaday provides viewers with direct links on how they can learn more about some of the data and information he’s shared with the public regarding the COVID-19 vaccine roll-outs:
Dr Peter Canaday – Pfizer Vaccine Discussion At The Town Hall
Courageous Convos with Special Guest Peter Canaday
Voices of Freedom on Odysee : search Peter Canaday
Dr. Canaday’s HBOT News Conversations is a two part series. Part 2 will air on Friday, December 16, 2022.
This HBOT News Conversation was filmed on October 4, 2022
Guest
Dr. Peter Canaday
Following completion of medical school at the University of Massachusetts in 1976, Dr. Peter Canaday took up training as an Internal Medicine specialist at the University of Michigan, followed by sub-specialist training in Respiratory and Intensive Care at the University of North Carolina. He began his medical career in a busy trauma hospital in Denver, Colorado in 1981 and practiced for 12 years. During his time there, he managed many of the types of patients now seen with severe COVID-19, co-founded a sleep disorders laboratory and a hyperbaric medicine department. As well, he participated in a dozen committee assignments, and rose to Chairman of the Department of Internal Medicine. In 1993, Dr Canaday changed career and completed training as a Radiologist at the University of Wisconsin in 1997. During an 8-year period at Creighton University Medical School in Nebraska, he became tenured as an Assistant Professor of Radiology, and head of the section of Pulmonary Radiology. He also served on or chaired over a dozen hospital and medical school committees and was appointed Clinical Coordinator for the Radiology Department during his time there. Dr Canaday has also published work in applied physiology, respiratory medicine, and diagnostic radiology, has presented at national (USA) and international meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on national, state, and local level advisory committees and given testimony at the state legislative level in the USA. From 2007, Dr Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at the Taranaki District Health Board and served as Head of Department before retiring in March 2021.
Subscribe Now, It’s Free!
Recent HBOT News
Hyperbaric oxygen and burns: an editorial perspective.
Abstract: Hunt, , , , , , , , (). Hyperbaric oxygen and burns: an editorial perspective. Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc, ;40(1):5. https://www.ncbi.nlm.nih.gov/pubmed/23397862
Clinical Trial – A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude
Acute exposure of the unacclimatized human body to high altitude leads to health
complications, such as loss of exercise performance capacity and fatigue. The investigators
have found that the combination of the xanthine drug theophylline and the endothelin receptor
antagonist ambrisentan improves the exercise performance capacity of rats under simulated
high altitude. In young, healthy human volunteers, this combination of drugs has not increase
toxicity over the single compounds under sea-level conditions. The aim of this study is to
test whether the combination of theophylline, supplied as its more soluble formulation
aminophylline, and ambrisentan, are also safe to take under simulated high altitude of 4,267
meters, under both resting and exercising conditions. The study also aims to test whether
this drug combination improves exercise capacity in humans. In this study, human subjects
will be randomized to one of four treatment sequences and receive the same study drug(s)
throughout all procedures. The study consists of an initial exercise test, followed by two
cycles of drug testing at simulated high altitude: Cycle 1 – resting subjects receiving study
drug at simulated altitude and continually monitored for safety with pharmacodynamic and
pharmacokinetic assessments; and Cycle 2, the same as Cycle 1, with the addition of exercise
testing. It is hypothesized that the combination of aminophylline and ambrisentan is not only
safe under simulated high altitude, but also improves exercise performance capacity, in
comparison with placebo.
Hyperbaric oxygen treatment.
Abstract: Marois, , , , , , , , (2013). Hyperbaric oxygen treatment. Annals of neurology, 2013 Jul;74(1):149. https://www.ncbi.nlm.nih.gov/pubmed/23483559